Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.66 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122468 | 0.93 | ESR2 (0.59) | ESR2NR1H2MAPK1MAPTNPC1 | |
| SCHEMBL31054069 | 0.92 | ESR2 (0.68) | ESR2NR1H2MAPK1MAPTHDAC1 | |
| SCHEMBL5599903 | 0.92 | ESR2 (0.72) | ESR2NR1H2MAPK1MAPTHDAC1 | |
| SCHEMBL31359293 | 0.92 | ESR2 (0.72) | ESR2NR1H2MAPK1MAPTHDAC1 | |
| SCHEMBL18875035 | 0.85 | NR1H2 (0.67) | ESR2NR1H2MAPK1MAPTHDAC1 | |
| SCHEMBL21470912 | 0.85 | ESR2 (0.64) | ESR2NR1H2MAPK1MAPTHDAC1 | |
| SCHEMBL2805947 | 0.85 | ESR2 (0.61) | ESR2NR1H2MAPK1MAPTHDAC1 | |
| SCHEMBL23684548 | 0.85 | ESR2 (0.68) | ESR2NR1H2MAPK1MAPTHDAC1 | |
| SCHEMBL23684302 | 0.85 | ESR2 (0.64) | ESR2NR1H2MAPK1MAPTHDAC1 | |
| SCHEMBL4183582 | 0.85 | NR1H2 (0.67) | ESR2NR1H2MAPK1MAPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179065-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2025101738-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2023150203-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150203-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2022169985-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | ESR2 3607/4885NR1H2 1754/4885MAPK1 2733/4885 |
| US-20250179065-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | ESR2 3607/4885NR1H2 1754/4885MAPK1 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.